295 related articles for article (PubMed ID: 24999371)
1. Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.
Desjardins M; Xie J; Gurler H; Muralidhar GG; Sacks JD; Burdette JE; Barbolina MV
J Ovarian Res; 2014; 7():70. PubMed ID: 24999371
[TBL] [Abstract][Full Text] [Related]
2. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
3. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
Klymenko Y; Kim O; Loughran E; Yang J; Lombard R; Alber M; Stack MS
Oncogene; 2017 Oct; 36(42):5840-5851. PubMed ID: 28628116
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
5. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
[TBL] [Abstract][Full Text] [Related]
6. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
7. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
[TBL] [Abstract][Full Text] [Related]
8. P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions.
Usui A; Ko SY; Barengo N; Naora H
Mol Cancer Res; 2014 Apr; 12(4):504-13. PubMed ID: 24448686
[TBL] [Abstract][Full Text] [Related]
9. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
10. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
[TBL] [Abstract][Full Text] [Related]
11. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.
Pan Y; Robertson G; Pedersen L; Lim E; Hernandez-Herrera A; Rowat AC; Patil SL; Chan CK; Wen Y; Zhang X; Basu-Roy U; Mansukhani A; Chu A; Sipahimalani P; Bowlby R; Brooks D; Thiessen N; Coarfa C; Ma Y; Moore RA; Schein JE; Mungall AJ; Liu J; Pecot CV; Sood AK; Jones SJ; Marra MA; Gunaratne PH
Oncotarget; 2016 May; 7(18):25930-48. PubMed ID: 27036018
[TBL] [Abstract][Full Text] [Related]
12. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.
Burleson KM; Casey RC; Skubitz KM; Pambuccian SE; Oegema TR; Skubitz AP
Gynecol Oncol; 2004 Apr; 93(1):170-81. PubMed ID: 15047232
[TBL] [Abstract][Full Text] [Related]
13. An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids.
Pettee KM; Dvorak KM; Nestor-Kalinoski AL; Eisenmann KM
PLoS One; 2014; 9(2):e90371. PubMed ID: 24587343
[TBL] [Abstract][Full Text] [Related]
14. Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.
Kim M; Rooper L; Xie J; Kajdacsy-Balla AA; Barbolina MV
Mol Cancer Res; 2012 Jan; 10(1):11-24. PubMed ID: 22064656
[TBL] [Abstract][Full Text] [Related]
15. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
16. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
17. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids--evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium.
Stadlmann S; Feichtinger H; Mikuz G; Marth C; Zeimet AG; Herold M; Knabbe C; Offner FA
Int J Gynecol Cancer; 2014 Feb; 24(2):192-200. PubMed ID: 24407573
[TBL] [Abstract][Full Text] [Related]
18. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
19. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.
Ween MP; Hummitzsch K; Rodgers RJ; Oehler MK; Ricciardelli C
Clin Exp Metastasis; 2011 Feb; 28(2):113-25. PubMed ID: 21153687
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
